May 18, 2018 09:56 AM EDT
News Briefing

As­traZeneca drops or di­vests a slate of drugs in lat­est quar­ter­ly up­date; Pierre Fab­re ex­tends a di­ag­nos­tic col­lab­o­ra­tion with Roche

John Carroll

Editor & Founder

→ With prof­its in de­cline as gener­ic Crestor com­pe­ti­tion bits in­to its cash flow, As­traZeneca not­ed the end of sev­er­al in-house pro­grams to­day as they …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

The End­points 100: The biotech in­dus­try braces for Trump 2.0

Lil­ly’s oral SERD makes strides in breast can­cer with Phase 3 da­ta

Ex­clu­sive: Bain-backed mus­cu­loskele­tal biotech rais­es $120M for trio of clin­i­cal-stage bi­o­log­ics

Chro­ma, Nvel­op merge to form nChro­ma Bio, rais­ing $75M to en­ter the clin­ic

Ace­lyrin says good­bye to the drug that got it a $540M IPO in 2023

sponsored

The key to faster, more im­pact­ful re­search? Put pa­tients in the dri­ver’s seat

A service from the Financial Times